Literature DB >> 12955398

Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies.

I Ferrer1, I Hernández, M Boada, A Llorente, M J Rey, A Cardozo, M Ezquerra, B Puig.   

Abstract

The clinical, neuroradiological, neuropathological and biochemical findings in four patients with primary progressive aphasia and tauopathy are described. The aphasic syndrome preceded by several years the appearance of other symptoms in every case. Asymmetrical apraxia with alien hand phenomenon occurred in one case. Frontotemporal symptoms occurred in three cases, but progressed to dramatic cognitive devastation in only one of these. Generalized dementia consistent with probable Alzheimer's disease (AD) developed with time in another. Cerebral computer tomography scans, magnetic resonance imaging and SPECT studies revealed marked asymmetries in one case, and showed nonspecific cerebral atrophy in the remaining ones. The neuropathological examination revealed typical corticobasal degeneration (CBD) in one case; CBD and AD in another; and atypical CBD, argyrophilic grain disease (AGD) and alpha-synucleinopathy consistent with Parkinson's disease in a third. Unique neuropathological findings were found in the remaining case. This was characterized by severe cerebral atrophy, marked neuronal loss in the cerebral cortex and abnormal tau deposition in neurons of the cerebral cortex, diencephalon and brain stem. Ballooned neurons, Pick bodies, generalized cortical neurofibrillary tangles and astrocytic plaques were absent. However, massive globular inclusions, containing phospho-tau, occurred in glial cells, mainly oligodendrocytes, in the white matter. Biochemical studies of frontal homogenates revealed four bands of 73/74, 68, 64 and 60 kDa of phosphorylated tau (using antibodies recognizing phospho-tau Thr181, Ser262 and Ser422) in the patient with AD and CBD, suggesting a predominant AD pattern in this case. Two bands of 68 and 64 kDa of phospho-tau were recovered in the sarkosyl-insoluble fraction in the other three cases. This pattern is similar to that found in CBD, progressive supranuclear palsy and AGD. Taken together, the present series further supports pure and combined CBD as causes of primary progressive aphasia, and they extend the hypothesis that primary progressive aphasia may be the initial symptom of distinct tauopathies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955398     DOI: 10.1007/s00401-003-0756-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  22 in total

1.  Globular glial tauopathies (GGT): consensus recommendations.

Authors:  Zeshan Ahmed; Gabor G Kovacs; Eileen H Bigio; Herbert Budka; Dennis W Dickson; Isidro Ferrer; Bernardino Ghetti; Giorgio Giaccone; Kimmo J Hatanpaa; Janice L Holton; Keith A Josephs; James Powers; Salvatore Spina; Hitoshi Takahashi; Charles L White; Tamas Revesz
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

2.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Authors:  Laetitia Troquier; Raphaelle Caillierez; Sylvie Burnouf; Francisco J Fernandez-Gomez; Marie-Eve Grosjean; Nadege Zommer; Nicolas Sergeant; Susanna Schraen-Maschke; David Blum; Luc Buee
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

3.  Extrapyramidal signs in the primary progressive aphasias.

Authors:  Sarah A Kremen; Mario F Mendez; Po-Heng Tsai; Edmond Teng
Journal:  Am J Alzheimers Dis Other Demen       Date:  2011-02       Impact factor: 2.035

4.  A novel tau mutation, p.K317N, causes globular glial tauopathy.

Authors:  Pawel Tacik; Michael DeTure; Wen-Lang Lin; Monica Sanchez Contreras; Aleksandra Wojtas; Kelly M Hinkle; Shinsuke Fujioka; Matthew C Baker; Ronald L Walton; Yari Carlomagno; Patricia H Brown; Audrey J Strongosky; Naomi Kouri; Melissa E Murray; Leonard Petrucelli; Keith A Josephs; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2015-04-22       Impact factor: 17.088

5.  Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy.

Authors:  P Tacik; M Sanchez-Contreras; M DeTure; M E Murray; R Rademakers; O A Ross; Z K Wszolek; J E Parisi; D S Knopman; R C Petersen; D W Dickson
Journal:  Neuropathol Appl Neurobiol       Date:  2017-03-08       Impact factor: 8.090

6.  Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings.

Authors:  M E Erro; M V Zelaya; M Mendioroz; R Larumbe; S Ortega-Cubero; J L Lanciego; A Lladó; T Cabada; T Tuñón; F García-Bragado; M R Luquin; P Pastor; I Ferrer
Journal:  J Neurol       Date:  2019-06-12       Impact factor: 4.849

7.  Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein.

Authors:  Jessica E Chukwu; Erin E Congdon; Einar M Sigurdsson; Xiang-Peng Kong
Journal:  MAbs       Date:  2019-02-26       Impact factor: 5.857

8.  Progressive supranuclear palsy and primary lateral sclerosis secondary to globular glial tauopathy: a case report and a practical theoretical framework for the clinical prediction of this rare pathological entity.

Authors:  Andy J Liu; Jessica E Chang; Georges Naasan; Adam L Boxer; Bruce L Miller; Salvatore Spina
Journal:  Neurocase       Date:  2020-02-23       Impact factor: 0.881

9.  Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration.

Authors:  Albert Lladó; Raquel Sánchez-Valle; Maria Jesús Rey; Mario Ezquerra; Eduardo Tolosa; Isidro Ferrer; José Luis Molinuevo
Journal:  J Neurol       Date:  2008-03-25       Impact factor: 4.849

10.  Dopamine promotes striatal neuronal apoptotic death via ERK signaling cascades.

Authors:  Jun Chen; Milan Rusnak; Paul J Lombroso; Anita Sidhu
Journal:  Eur J Neurosci       Date:  2009-01       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.